Due to the promising results of tucatinib, there are several clinical trials exploring the effect of the combination of tucatinib with T-DM1 (NCT04457596, NCT03975647, NCT01983501, and NCT05323955), with T-DXd (NCT04539938 and NCT04538742), and with CDK4/6 inhibitors (NCT03054363) in HER2+ breast cancer patients. Here, ERBB2 is linked to breast cancer.